Showing results (251-260 of 281) with videos related to

Sort By:
Pageof 29
Biomarker Research|July 23, 2025
Multiple ctDNA- based biomarkers predict benefit from selective RET Inhibition in non-small cell lung cancer patients: exploratory analysis of a prospective studyChang Lu, Chong-Rui Xu, Yi-Chen Zhang, et al.
Cell Reports. Medicine|January 19, 2023
Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world studyHan-Min Wang, Chan-Yuan Zhang, Kai-Cheng Peng, et al.
Science Bulletin|January 7, 2024
PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trialSi-Yang Maggie Liu, Jie Huang, Jia-Yi Deng, et al.
Journal of Extracellular Vesicles|October 4, 2019
Plasma extracellular vesicle microRNAs for pulmonary ground-glass nodulesJia-Tao Zhang, Hao Qin, Fiona Ka Man Cheung, et al.
Clinical Lung Cancer|October 14, 2021
Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable TargetsHai-Yan Tu, Yang-Si Li, Xiao-Yan Bai, et al.
Molecular Oncology|April 20, 2023
Genomic and immune characteristics of HER2-mutated non-small-cell lung cancer and response to immune checkpoint inhibitor-based therapyHai-Yan Tu, Kai Yin, Xiaotian Zhao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2017
Detection of Driver and Resistance Mutations in Leptomeningeal Metastases of NSCLC by Next-Generation Sequencing of Cerebrospinal Fluid Circulating Tumor CellsBen-Yuan Jiang, Yang-Si Li, Wei-Bang Guo, et al.
Signal Transduction and Targeted Therapy|February 23, 2023
Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trialWen-Zhao Zhong, Hong-Hong Yan, Ke-Neng Chen, et al.
Frontiers in Immunology|October 20, 2022
PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinomaYu-Min Zhong, Kai Yin, Yu Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 12, 2017
Acquired <i>MET</i> Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung CancerAnna Li, Jin-Ji Yang, Xu-Chao Zhang, et al.
Pageof 29